Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent, Inc. (historically NYSE: CTLT) generates frequent news as a global contract development and manufacturing organization (CDMO) serving pharma, biotech, and consumer health customers. Company announcements emphasize its mission to develop, manufacture, and supply products that help people live better and healthier lives, as well as its role in optimizing product development, launch, and full life-cycle supply.
News about Catalent often covers its corporate transactions and ownership structure. A major recent theme has been the acquisition of Catalent by Novo Holdings A/S, a global life sciences investment firm. Press releases detail the signing of the merger agreement, regulatory approvals, fulfillment of closing conditions, and the completion of the all-cash transaction, after which Catalent became a private company and its common stock ceased trading on the New York Stock Exchange.
Operational updates are another key news category. Catalent has reported expansions of its global network, such as the completion of a significant expansion at its Schorndorf, Germany clinical supply facility, adding temperature-controlled storage, a new automatic bottle filling line, and dedicated space for its FastChain demand-led supply service. The company has also announced portfolio changes, including an agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, which also houses its corporate headquarters during a transition period.
Financial results and segment performance feature prominently in Catalent’s news flow. The company publishes quarterly and annual results, including net revenue, segment performance for Biologics and Pharma and Consumer Health, and non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income, along with commentary on trends in non-COVID revenue and leverage ratios.
Governance and leadership developments also appear in Catalent’s news, such as new Board appointments and updates to its Board composition under Novo Holdings’ ownership. For readers tracking CTLT-related developments, this news stream provides context on Catalent’s evolution from a public CDMO to a privately held company, its investment in global capacity, and its ongoing role in supporting the development and supply of treatments worldwide.
Catalent has announced that Alessandro Maselli will be the new President and CEO, effective July 1, 2022. Maselli, previously President and COO, has been with the company for over 11 years and played a crucial role in its strategy, including the delivery of over 1 billion COVID-19 vaccine doses. Current CEO John Chiminski will transition to Executive Chair on the same date. This leadership change is seen as a continuation of Catalent's growth trajectory and a commitment to its role in the healthcare sector.
Melt Pharmaceuticals announced the filing of two INDs with the FDA for non-opioid formulations MELT-210 and MELT-400. The company is actively dosing patients for its Phase 2 pivotal efficacy study of MELT-300, which is expected to complete enrollment by early Q2 2022. MELT-300 offers a needle-free, opioid-free alternative for sedation during cataract surgeries, potentially eliminating the need for opioids and contributing to addressing the opioid crisis. Top-line results are anticipated by the end of Q2 2022.
Catalent, a global leader in advanced delivery technologies, announced its executive team will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 7:30 a.m. ET. A live webcast of the presentation can be accessed on their investor website and will be available for replay afterward.
With over 17,000 employees and $4 billion in revenue for fiscal 2021, Catalent supports over 1,000 partner programs annually, optimizing product development and supply for the biopharma and consumer health industries.
Edenbridge Pharmaceuticals has received FDA approval for DARTISLA ODT, its first 505(b)(2) branded drug. This orally disintegrating tablet, containing 1.7 mg of glycopyrrolate, is indicated for adults to alleviate peptic ulcer symptoms. DARTISLA ODT is notable as the first and only orally disintegrating tablet formulation of glycopyrrolate. The product is set to launch in early 2022, marking a significant milestone for Edenbridge as it expands into the branded specialty prescription market.
Catalent, Inc. (NYSE: CTLT) announced that its executive leadership will present virtually at the Stephens Annual Investment Conference on November 29, 2021 at 11:00 a.m. ET. A live webcast will be available at investor.catalent.com and can be replayed post-event. Catalent is a leader in enabling pharma, biotech, and consumer health partners to optimize product development and supply, generating $4 billion in revenue in fiscal 2021 with over 17,000 employees across 50 global sites.
Catalent, Inc. (CTLT) reported Q1'22 net revenue of $1.03 billion, up 21% year-over-year, reflecting 23% organic growth. Net earnings for the quarter reached $93 million with an Adjusted EBITDA of $252 million, marking a 44% increase. The company also acquired Bettera for $1 billion, enhancing its position in the nutritional supplements market. Catalent raised its fiscal 2022 guidance, projecting net revenue of $4.62 billion to $4.82 billion and Adjusted EBITDA of $1.225 billion to $1.295 billion.
Catalent, Inc. (NYSE: CTLT) will announce its first-quarter fiscal results for 2022 on November 2, 2021, before the market opens. A live webcast is scheduled for 8:15 a.m. ET to discuss these results. The supplemental slides will be available in the 'Investors' section of Catalent’s website prior to the webcast. With a workforce of over 17,000 and nearly 90 years in the industry, Catalent reported $4 billion in annual revenue during fiscal year 2021, establishing itself as a leader in developing manufacturing platforms for medicines.
Catalent, Inc. (NYSE: CTLT) announced a private offering of $650 million in senior unsecured notes due 2030, increasing the offering size by $200 million. The proceeds will finance the acquisition of Bettera Holdings, LLC and cover related costs. The notes will be guaranteed by U.S. subsidiaries of Catalent Pharma Solutions but not by Catalent itself. The offering is exempt from SEC registration requirements under Rule 144A and Regulation S and is expected to close on September 29, 2021.
Catalent, Inc. (NYSE: CTLT) announced a private offering of $450 million in senior unsecured notes due 2030 through its subsidiary, Catalent Pharma Solutions. The proceeds will finance part of the acquisition of Bettera Holdings and cover related expenses. The notes will be available to qualified institutional buyers and certain non-U.S. investors. They will not be guaranteed by Catalent or its parent companies. The offering is not registered under the Securities Act, and there are no assurances that either the offering or the acquisition will be completed successfully.
Catalent, Inc. (NYSE: CTLT) announced that its executive leadership will present virtually at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 1:15 a.m. ET. A live webcast of the presentation will be available for viewing at investor.catalent.com and can be replayed afterwards. Catalent is a global leader in development sciences and manufacturing for medicines, boasting nearly 90 years in the industry, 17,000 employees, and $4 billion in fiscal year 2021 revenue.